How Many Novo Nordisk A/S (NYSE:NVO)’s Analysts Are Bullish?

April 22, 2018 - By Henry Gaston

Novo Nordisk A/S (NYSE:NVO) Logo

Novo Nordisk A/S (NYSE:NVO) Ratings Coverage

Among 6 analysts covering Novo Nordisk A\/S Common Stock (NYSE:NVO), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Novo Nordisk A\/S Common Stock had 6 analyst reports since December 1, 2017 according to SRatingsIntel. The firm earned “Overweight” rating on Friday, December 1 by Morgan Stanley. The firm earned “Buy” rating on Friday, January 19 by Goldman Sachs. The stock of Novo Nordisk A/S (NYSE:NVO) earned “Hold” rating by J.P. Morgan on Friday, December 29. JP Morgan upgraded the shares of NVO in report on Friday, December 29 to “Neutral” rating. The stock of Novo Nordisk A/S (NYSE:NVO) earned “Buy” rating by Bank of America on Wednesday, December 6. Below is a list of Novo Nordisk A/S (NYSE:NVO) latest ratings and price target changes.

19/01/2018 Broker: Goldman Sachs Rating: Buy Maintain
08/01/2018 Broker: Deutsche Bank Rating: Buy
29/12/2017 Broker: J.P. Morgan Rating: Hold Upgrade
29/12/2017 Broker: JP Morgan Old Rating: Underweight New Rating: Neutral Upgrade
06/12/2017 Broker: Bank of America Rating: Buy Upgrade
01/12/2017 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Overweight Upgrade

The stock decreased 0.90% or $0.43 during the last trading session, reaching $47.23. About 2.59 million shares traded or 66.94% up from the average. Novo Nordisk A/S (NYSE:NVO) has risen 42.07% since April 22, 2017 and is uptrending. It has outperformed by 30.52% the S&P500.

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. The company has market cap of $114.05 billion. It operates in two divisions, Diabetes and Obesity Care, and Biopharmaceuticals. It has a 18.61 P/E ratio. The Diabetes and Obesity Care segment provides insulins, GLP-1 analog, and oral anti-diabetic drugs, as well as other protein related products comprising glucagon, protein related delivery systems, and needles.

Novo Nordisk A/S (NYSE:NVO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.